ArticleCancer cell2016
CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.
Open access · bronzeAbstract readComment
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 122 citations in OpenAlex.
- Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.Blood advances · 2024Trial
- Asymmetric division sustains stem cell heterogeneity in the Drosophila testicular niche.Communications biology · 2026Article
- A Gold-PROTAC Degrades the Oncogenic Tyrosine Kinase MERTK: Insights into the Degradome from a Steady-State System.ACS chemical biology · 2026Article
- Article
- Integrated in vivo functional screens and multiomics analyses identify α-2,3-sialylation as essential for melanoma maintenance.Science advances · 2025Article
- Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.Biomarker research · 2025Review
- Screening the human miRNA interactome reveals coordinated up-regulation in melanoma, adding bidirectional regulation to miRNA networks.Science advances · 2025Article
- CD98hc, a novel of galectin-8 receptor, binds to galectin-8 in an N-glycosylation-dependent manner.Acta biochimica et biophysica Sinica · 2025Article
- Flow cytometric detection of leukemic stem cells in Acute Myeloid Leukemia: current status and future directions.Frontiers in pharmacology · 2025Review
- Asymmetric stem cell division maintains genetic heterogeneity of tissue cells.bioRxiv : the preprint server for biology · 2024Article
- Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Imaging Approaches in Cancer Biology.Cold Spring Harbor perspectives in medicine · 2024Review
- Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview.International journal of molecular sciences · 2024Review
- CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy.Scientific reports · 2024Article
- Temporal Single Cell Analysis of Leukemia Microenvironment Identifies Taurine-Taurine Transporter Axis as a Key Regulator of Myeloid Leukemia.bioRxiv : the preprint server for biology · 2024Article
- Metabolic alterations of peripheral blood immune cells and heterogeneity of neutrophil in intracranial aneurysms patients.Clinical and translational medicine · 2024Article
- Comprehensive analysis of disulfidptosis-related genes and the immune microenvironment in heart failure.Frontiers in cell and developmental biology · 2024Article
- Article
- Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia.Journal of visualized experiments : JoVE · 2023Article
- SLC3A2 promotes tumor-associated macrophage polarization through metabolic reprogramming in lung cancer.Cancer science · 2023Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
14 authors at 6 institutions in 2 countries.
Jeevisha BajajDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Takaaki KonumaDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Nikki K LytleDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Hyog Young KwonDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Jailal N AblackDepartment of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Joseph M CantorDepartment of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
David RizzieriDivision of Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Charles ChuahDepartment of Haematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore.
Vivian G OehlerClinical Research Division, Fred Hutchinson Cancer Research Center, WA 98109, USA.
Elizabeth H BroomeMoores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Edward D BallMoores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, Blood and Marrow Transplantation Division, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.
Edward H van der HorstIgenica Biotherapeutics Inc., Burlingame, CA 94010, USA.
Mark H GinsbergMoores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: mhginsberg@ucsd.edu.
Tannishtha ReyaDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92093, USA. Electronic address: treya@ucsd.edu.
University of California, San Diego · USSanford Consortium for Regenerative Medicine · USDuke Medical Center · USDuke-NUS Medical School · SGFred Hutch Cancer Center · USJuvaris BioTherapeutics (United States) · US
Funding
The Interaction of TPO and Integrins in Hematopoiesis CellsP01HL078784 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2005 to 2019
$28.3MGRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MMolecular strategies for early detection and targeting of cancerR35CA197699 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tannishtha Reya · 2015 to 2026
$11.2MBlood Cells in Hemostasis and ThrombosisT32HL086344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2008 to 2023
$4.4MComposition and Functions of the Integrin Activation ComplexR01HL117807 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2014 to 2017
$1.5MMolecular Determinants of Asymmetric DivisionR01DK099335 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI REYA, TANNISHTHA · 2014 to 2017
$1.5MImaging self-renewal and transformation in hematopoietic stem cellsDP1CA174422 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI REYA, TANNISHTHA · 2012 to 2013
$1.5MImaging the stem cell niche in regeneration and cancerR01HL097767 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI REYA, TANNISHTHA · 2009 to 2012
$1.5MStem cell signals in pancreatic adenocarcinoma metastasis and therapy resistanceF31CA206416 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LYTLE, NIKKI KATHERINE · 2016 to 2017
$75kNCI NIH HHS DP1 CA174422NCI NIH HHS F31 CA206416NCI NIH HHS R35 CA197699NHLBI NIH HHS P01 HL078784NHLBI NIH HHS R01 HL097767NHLBI NIH HHS R01 HL117807NHLBI NIH HHS T32 HL086344NIDDK NIH HHS R01 DK099335NIGMS NIH HHS T32 GM007752
Abstract
Acute myelogenous leukemia (AML) is an aggressive disease associated with drug resistance and relapse. To improve therapeutic strategies, it is critical to better understand the mechanisms that underlie AML progression. Here we show that the integrin binding glycoprotein CD98 plays a central role in AML. CD98 promotes AML propagation and lethality by driving engagement of leukemia cells with their microenvironment and maintaining leukemic stem cells. Further, delivery of a humanized anti-CD98 antibody blocks growth of patient-derived AML, highlighting the importance of this pathway in human disease. These findings indicate that microenvironmental interactions are key regulators of AML and that disrupting these signals with targeted inhibitors such as CD98 antibodies may be a valuable therapeutic approach for adults and children with this disease.
Indexed as
AnimalsAntibodiesCell AdhesionCell Line, TumorCell ProliferationFusion Regulatory Protein-1Gene Knockout TechniquesHumansLeukemia, Myeloid, AcuteMiceNeoplasm TransplantationNeoplastic Stem CellsAntibodiesFusion Regulatory Protein-1acute myelogenous leukemiaadhesioncancercancer stem cellCD98imagingintegrinleukemiamicroenvironmentSLC3A2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.